Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 9,981	$ 2,336
Available-for-sale investments	56,165	105,575
Other receivables	11,775	435
Prepaid expenses	2,950	5,223
Total current assets	80,871	113,569
Restricted cash	3,165	0
Property and equipment, net	3,059	543
Operating lease, right-of-use assets	7,250	1,267
Financing lease, right-of-use assets	1,248	0
Other assets	193	158
Total assets	95,786	115,537
Current liabilities:
Accounts payable	3,106	1,031
Accrued expenses	9,862	4,002
Current portion of operating lease liability	630	980
Current portion of financing lease liability	264	0
Total current liabilities	13,862	6,013
Long-term operating lease liability, net of current portion	9,633	398
Long-term financing lease liability, net of current portion	1,007	0
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of December 31, 2022 and 2021, respectively; no shares issued or outstanding as of December 31, 2022 and 2021, respectively
Common stock, $0.001 par value per share; 85,000,000 and 42,500,000 authorized shares as of December 31, 2022 and 2021, respectively; issued and outstanding shares - 29,498,488 and 27,793,035 as of December 31, 2022 and 2021, respectively	29	28
Additional paid-in capital	489,502	481,832
Accumulated other comprehensive loss	(433)	(263)
Accumulated deficit	(417,634)	(372,296)
Total aTyr Pharma stockholders’ equity	71,464	109,301
Noncontrolling interest in Pangu BioPharma Limited	(180)	(175)
Total stockholders' equity	71,284	109,126
Total liabilities and stockholders’ equity	$ 95,786	$ 115,537